The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).
 
Sant P. Chawla
Stock and Other Ownership Interests - AADi; Cellestia Biotech; Immix BioPharma
Honoraria - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma; Tyme
Consulting or Advisory Role - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Speakers' Bureau - Amgen; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; Janssen; Karyopharm Therapeutics; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
Research Funding - Advenchen Laboratories; Amgen; Bayer; CytRx Corporation; GlaxoSmithKline; Ignyta; Immune Design; InhibRx; Janssen; Janssen; Karyopharm Therapeutics; NKMax; Roche; SARC: Sarcoma Alliance for Research though Collaboration; Threshold Pharmaceuticals; TRACON Pharma
 
Gerald Steven Falchook
Employment - HealthONE; Sarah Cannon Research Institute
Honoraria - Rocky Mountain Oncology Society
Consulting or Advisory Role - EMD Serono; Fujifilm (Inst); Navire (Inst); Silicon Therapeutics (Inst)
Speakers' Bureau - Total Health Conferencing
Research Funding - 3-V Biosciences (Inst); Abbisko (Inst); Abbvie (Inst); ADC Therapeutics (Inst); Aileron Therapeutics (Inst); Amgen (Inst); ARMO BioSciences (Inst); AstraZeneca (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); Bioatla (Inst); BioInvent (Inst); Biothera (Inst); Celgene (Inst); Celldex (Inst); Ciclomed (Inst); Curegenix (Inst); Curis (Inst); Cyteir (Inst); Daiichi (Inst); DelMar Pharmaceuticals (Inst); eFFECTOR Therapeutics (Inst); EMD Serono (Inst); Epizyme (Inst); Exelixis (Inst); Fujifilm (Inst); Genmab (Inst); Hutchison MediPharma (Inst); IgM Biosciences (Inst); Ignyta (Inst); Immunogen/MacroGenics (Inst); Incyte (Inst); Jacobio (Inst); Jounce Therapeutics (Inst); Kolltan Pharmaceuticals (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Millennium (Inst); miRNA Therapeutics (Inst); Navire (Inst); Novartis (Inst); OncoMed (Inst); Oncorus (Inst); poseida therapeutics (Inst); Precision Oncology (Inst); Prelude Therapeutics (Inst); PureTech (Inst); Regeneron (Inst); Rgenix (Inst); Ribon Therapeutics (Inst); Sapience Therapeutics (Inst); Silicon Therapeutics (Inst); Strategia Therapeutics (Inst); Syndax (Inst); Synthorx (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Tarveda Therapeutics (Inst); Tesaro (Inst); Tocagen (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst); Xencor (Inst)
Patents, Royalties, Other Intellectual Property - Handbook of Targeted Cancer Therapy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; EMD Serono; Fujifilm; Millennium; Sarah Cannon Research Institute
 
Melissa Amber Burgess
Consulting or Advisory Role - EMD Serono
Research Funding - Merck
Travel, Accommodations, Expenses - SpringWorks Therapeutics
(OPTIONAL) Uncompensated Relationships - TRACON Pharma
 
James Lin Chen
Consulting or Advisory Role - Syapse
Speakers' Bureau - Foundation Medicine
Research Funding - Eisai
Patents, Royalties, Other Intellectual Property - MatchTX
 
Robin Lewis Jones
Consulting or Advisory Role - Adaptimmune; Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim; Clinigen Group; Daiichi Sankyo; Deciphera; Eisai; Epizyme; Immodulon Therapeutics; Immune Design; Karma Oncology; Lilly; Merck Serono; Morphotek; PharmaMar; TRACON Pharma; UpToDate
Research Funding - GlaxoSmithKline (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Victoria S. Chua
No Relationships to Disclose
 
Coya Tapia
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
Honoraria - Epizyme
Research Funding - ARMO BioSciences; Merck; Pfizer
 
Jessica Ainscough
Employment - Epizyme
Stock and Other Ownership Interests - Epizyme
Research Funding - Epizyme
 
Anthony Hamlett
No Relationships to Disclose
 
Melinda S. Merchant
Employment - AstraZeneca; Epizyme
Stock and Other Ownership Interests - AstraZeneca; Epizyme
Patents, Royalties, Other Intellectual Property - AstraZeneca; Epizyme
 
Rashmi Chugh
Consulting or Advisory Role - Deciphera; Deciphera; Ipsen
Research Funding - AADi (Inst); Advenchen Laboratories (Inst); Epizyme (Inst); GlaxoSmithKline (Inst); Lilly (Inst); MabVax (Inst); Medivation (Inst); Morphotek (Inst); Mundipharma (Inst); Novartis (Inst); Pfizer (Inst); Plexxikon (Inst); Qilu Puget Sound Biotherapeutics (Inst); Qilu Puget Sound Biotherapeutics (Inst); SpringWorks Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Wolters Kluwer
Travel, Accommodations, Expenses - SpringWorks Therapeutics